News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Isotechnika Inc.'s Phase III Psoriasis Spirit Trial Achieves Safety And Efficacy Endpoints
November 7, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
EDMONTON, Nov. 7 /PRNewswire-FirstCall/ - Isotechnika Inc. announced today the unaudited 24 week data for the Company's Canadian Phase III psoriasis trial for its lead immunosuppressive drug, ISA247.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
MORE ON THIS TOPIC
Radiopharmaceuticals
Sanofi Comes for Novartis’ Radiopharma Crown With ‘Clinically Meaningful’ Pancreatic Tumor Data
October 8, 2025
·
2 min read
·
Annalee Armstrong
Podcast
Shutdown Pauses New Drug Reviews, CDC Issues New COVID Guidance, CGT Meets on Mesa
October 8, 2025
·
1 min read
·
Heather McKenzie
Obesity
Skye’s CB1 Inhibitor Shows ‘Intriguing Synergy’ With Wegovy, Despite Mid-Stage Obesity Fail
October 7, 2025
·
2 min read
·
Tristan Manalac
Cell and Gene Therapy
Meeting on the Mesa Arrives Amid Mixed Signals for Cell and Gene Therapy
October 6, 2025
·
5 min read
·
Ben Hargreaves
